Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer - PubMed (original) (raw)
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
Q Chang et al. Br J Cancer. 2008.
Abstract
Eph receptors constitute the largest family of receptor tyrosine kinases in the human genome. EphA2 is one prominent member that is overexpressed and functionally altered in many invasive cancers, including pancreatic cancer. Dasatinib, which is a multi-targeted kinase inhibitor mainly developed for Bcr-Abl and Src family kinases, has recently been shown to have significant activity against EphA2. As selective small molecule EphA2 inhibitors are not currently available, we investigated the therapeutic potential to target EphA2 by dasatinib in pancreatic cancer cell lines. Using in vitro kinase assays, we found that EphA2 receptor tyrosine kinase was inhibited directly by dasatinib in a dose-dependent manner. Stimulation with ephrinA1 produced rapid increases of EphA2 phosphorylation that were inhibited by dasatinib, although the effects on activation of downstream signalling differed among the pancreatic cancer cell lines. Dasatinib also inhibited ligand-induced binding of EphA2 to the ubiquitin ligase Cbl, and the internalisation and degradation of EphA2, suggesting that these processes are dependent on kinase activity. Treatment with dasatinib decreased EphA2 phosphorylation in BxPC-3 xenografts, suggesting that dasatinib might have activity in pancreatic cancer due to EphA2 inhibition, besides its effects on Src.
Figures
Figure 1
EphA2 receptor tyrosine kinase activity is inhibited directly by dasatinib. HEK-293 cell lysates transfected with EphA2 or EphB2 constructs were immunoprecipitated with anti-EphA2 or anti-EphB2 antibody and kinase assays were performed in the presence of increasing amounts of dasatinib. Inclusion of dasatinib resulted in decreased autophosphorylation. The same gel was exposed for 5 h (A) and then exposed for 20 h (B).
Figure 2
In vitro anti-tumour activity of dasatinib. BxPC-3, PANC-1 and MIA PaCa-2 cells were pretreated with 0, 25, 50, 100 and 200 n
M
dasatinib for 24 or 48 h. (A) Effects of 48 h treatment with dasatinib on the in vitro growth of BxPC-3, PANC-1 and MIA PaCa-2 cells at the indicated concentrations were measured by MTS assay. *Statistically significant from control (P<0.05). (B) Single parameter DNA histograms showed the cell cycle effects of 24 h treatment with dasatinib at the indicated concentrations. Percent cells in G1-S-G2/M phase are given. CV, coefficient of variation.
Figure 3
Inhibition of EphA2 receptor tyrosine kinase signalling in pancreatic cancer cell lines. Around 90% confluent serum-starved BxPC-3, PANC-1 and MIA PaCa-2 cells were pretreated with or without 200 n
M
dasatinib for 2 h prior to 2 _μ_g ml−1 ephrinA1-Fc stimulation for the indicated periods of time. Cells were harvested at various time points. (A) Cell lysates were immunoprecipitated with anti-EphA2 antibody, analysed by phosphotyrosine (P-Tyr-100) and EphA2 immunoblots. The same membrane was exposed for 45 s (a) and then 10 min (b) using ECL Plus. EphA2 reprobing (c) served as the loading control. (B) Cell lysates were analysed by western blot using antibodies directed against phosphotyrosine (P-Tyr-100), p-Src (Tyr 416), Src, p-FAK (Tyr 576/577, Tyr 925), FAK, p-Paxillin (Tyr 118), Paxillin, p-Akt (Ser 473), Akt, p-ERK1/2 (Thr 202/Tyr 204), ERK1/2, p-STAT3 (Ser 727, Tyr 705), STAT3.
Figure 4
Inhibition of EphA2 receptor tyrosine kinase is dose-dependent. Around 90% confluent serum-starved BxPC-3 cells were pretreated with the indicated concentration of dasatinib or 20 μ
M
PP2 for 2 h prior to 2 _μ_g ml−1 ephrinA1-Fc stimulation for 5 min. Cell lysates were immunoprecipitated with anti-EphA2 antibody, analysed by phosphotyrosine (P-Tyr-100) and EphA2 immunoblots. The cell lysates were also analysed by western blot using the indicated antibodies.
Figure 5
Dasatinib inhibits ligand-induced EphA2 internalisation and degradation. Approximately 90% confluent BxPC-3, PANC-1 and MIA PaCa-2 cells were pretreated with 200 n
M
dasatinib for 2 h prior to 2 _μ_g ml−1 ephrinA1-Fc stimulation. (A) Cell lysates were immunoprecipitated with anti-Cbl or anti-EphA2 antibody 30 min following ligand stimulation, and analysed by EphA2, phosphotyrosine (P-Tyr-100) or Cbl immunoblots. Cell lysates were also analysed by western blot using anti-EphA2 or anti-Cbl antibody. _α_-Tubulin served as the loading control. (B) Cell lysates probed for EphA2 3 h following ligand activation. Densitometric data (fold change) are shown, normalised to _α_-tubulin. (C) The subcellular distribution of EphA2 30 min following ligand activation was evaluated using confocal microscopy. Contrast enhancement was applied uniformly to all panels.
Figure 6
Inhibition of EphA2 receptor tyrosine kinase signalling in BxPC-3 xenografts. Mice bearing BxPC-3 xenografts were treated with single dose of 50 mg kg−1 dasatinib or vehicle control for the indicated periods of time. The zero time points are drug vehicle controls. Tumour lysates were immunoprecipitated with anti-EphA2 antibody, analysed by phosphotyrosine (P-Tyr-100) and EphA2 immunoblots. The tumour lysates were also analysed by western blot using the indicated antibodies.
Similar articles
- Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R, Mesa T, Vultur A, Lee F, Jove R. Buettner R, et al. Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169. Mol Cancer Res. 2008. PMID: 19010823 Free PMC article. - Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ. Konecny GE, et al. Br J Cancer. 2009 Nov 17;101(10):1699-708. doi: 10.1038/sj.bjc.6605381. Epub 2009 Oct 27. Br J Cancer. 2009. PMID: 19861960 Free PMC article. - Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ, Crown J, Clynes M, O'Donovan N. Eustace AJ, et al. J Transl Med. 2008 Sep 29;6:53. doi: 10.1186/1479-5876-6-53. J Transl Med. 2008. PMID: 18823558 Free PMC article. - Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC, Seoane S, Ocaña A, Pandiella A. Montero JC, et al. Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Clin Cancer Res. 2011. PMID: 21670084 Review. - The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J, Debinski W. Wykosky J, et al. Mol Cancer Res. 2008 Dec;6(12):1795-806. doi: 10.1158/1541-7786.MCR-08-0244. Mol Cancer Res. 2008. PMID: 19074825 Free PMC article. Review.
Cited by
- Erythropoietin-induced hepatocyte receptor A2 regulates effect of pyroptosis on gastrointestinal colorectal cancer occurrence and metastasis resistance.
Zhang YK, Shi R, Meng RY, Lin SL, Zheng M. Zhang YK, et al. World J Gastrointest Oncol. 2024 Sep 15;16(9):3781-3797. doi: 10.4251/wjgo.v16.i9.3781. World J Gastrointest Oncol. 2024. PMID: 39350985 Free PMC article. Review. - Hypoxia-induced TGFBI maintains glioma stem cells by stabilizing EphA2.
Chen Z, Wang J, Peng P, Liu G, Dong M, Zhang X, Zhang Y, Yang X, Wan L, Xiang W, Zhang S, Zhang B, Wu Q, Yu X, Wan F. Chen Z, et al. Theranostics. 2024 Sep 9;14(15):5778-5792. doi: 10.7150/thno.95141. eCollection 2024. Theranostics. 2024. PMID: 39346536 Free PMC article. - Targeting the EphA2 pathway: could it be the way for bone sarcomas?
Giordano G, Tucciarello C, Merlini A, Cutrupi S, Pignochino Y. Giordano G, et al. Cell Commun Signal. 2024 Sep 9;22(1):433. doi: 10.1186/s12964-024-01811-7. Cell Commun Signal. 2024. PMID: 39252029 Free PMC article. Review. - The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies.
Ren J, Lv L, Tao X, Zhai X, Chen X, Yu H, Zhao X, Kong X, Yu Z, Dong D, Liu J. Ren J, et al. Front Pharmacol. 2024 Jul 26;15:1432545. doi: 10.3389/fphar.2024.1432545. eCollection 2024. Front Pharmacol. 2024. PMID: 39130630 Free PMC article. Review. - Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction.
Suda M, Paul KH, Tripathi U, Minamino T, Tchkonia T, Kirkland JL. Suda M, et al. Endocr Rev. 2024 Sep 12;45(5):655-675. doi: 10.1210/endrev/bnae010. Endocr Rev. 2024. PMID: 38500373 Free PMC article. Review.
References
- Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U, Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035–1044 - PubMed
- Batlle E, Bacani J, Begthel H, Jonkeer S, Gregorieff A, Born Mvd, Malats Nr, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435: 1126–1130 - PubMed
- Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J (2002) Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011–7026 - PubMed
- Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS (2002) Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62: 2840–2847 - PubMed
- Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B (2004) Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64: 910–919 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous